$HBNC

Piper Sandler upgrades Horizon Bancorp stock rating on valuation

Piper Sandler upgraded Horizon Bancorp (HBNC) to Overweight, raising its price target to $24.00. The firm cited the stock's discounted valuation, expected net interest margin gains, and balance sheet growth. HBNC trades at $19.08, with analysts predicting profitability this year. Recent earnings missed estimates, but the company showed improved net interest margin and steady credit quality.

Original reporting
Published Oct 2, 2026, 8:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$HBNC
Bullish
high confidence
Mentioned
$HBNC
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HBNCBullishHigh
01

Why it matters

The upgrade could trigger short‑term buying, supporting the stock's recent rally.

02

Market read

Analyst action on a small‑cap bank offers a clear trade idea for short‑term investors.

03

What to watch

Potential headwinds from higher interest rates and credit quality concerns.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

The article reports an analyst upgrade and price‑target increase for Horizon Bancorp, a small U.S. bank, following its Q2 earnings miss.

Company-level read

Ticker impact

$HBNCBullishHigh confidence
Context

Piper Sandler upgraded Horizon Bancorp to Overweight and raised the price target to $24, citing valuation and margin outlook.

Expected impact

likely upward pressure as investors price in the new target and improved margin expectations

Evidence & confidence

Analyst upgrade with a concrete price target change is a fresh catalyst that typically drives buying interest.

Market effects

Positive outlook for regional banks may lift peer valuations.

U.S. banking sector sentiment could improve modestly.

Limited to U.S. small‑cap banking niche.

Counterpoint

Some investors may view the upgrade as premature given recent earnings miss.

Key entities

  • Piper Sandler

    Provided the upgrade and new price target.

  • Horizon Bancorp

    Recipient of the upgrade; ticker HBNC.

Related articles

$HBNCLow

HORIZON BANCORP INC /IN/ (HBNC): Results of Operations and Financial Condition

HORIZON BANCORP INC /IN/ (HBNC) filed an SEC Form 8-K — Results of Operations and Financial Condition. 1 Contact: John R. Stewart Chief Financial Officer Phone: 219-814-5833 Date: October 1, 2026 Horizon Bancorp, Inc. Announces Conference Call to Review Third Quarter Results on October 22 MICHIGAN CITY, Ind., October 1, 2026 (GLOBE NEWSWIRE) -- (NASDAQ GS: HBNC) – Horizon Bancorp,

$HBNCMed

Horizon Bancorp (IN) Q2 Earnings Call Highlights

Horizon Bancorp (HBNC) reported Q2 credit quality stability, with net charge-offs of about $605,000 (5 bps annualized) and non-performing loans down to $34.9 million (0.70% of loans). Net interest margin rose 8 bps to 4.37%. Non-interest income increased 10% YoY. Management modestly raised 2026 outlook, including low-teens NII growth and NIM of 4.30% to 4.35% in 2H.

$HBNCMed

Horizon Bancorp, Inc. Reports Second Quarter 2026 Results

HORIZON BANCORP INC /IN/ (HBNC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hbnc-20260630earningsrelea.htm EX-99.1 Document Horizon Bancorp, Inc. Reports Second Quarter 2026 Results + Contact: John R. Stewart, CFA EVP, Chief Financial Officer Phone: (219) 814–5833 Fax: (219) 874–9280 Date: July 22, 2026 FOR IMMEDIATE RELEASE Horizon Bancorp, In

$HBNCLow

HORIZON BANCORP INC /IN/ (HBNC): Results of Operations and Financial Condition

HORIZON BANCORP INC /IN/ (HBNC) filed an SEC Form 8-K — Results of Operations and Financial Condition. hbnc-20260701 0000706129 false 0000706129 2026-07-01 2026-07-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) :

$LQDAHigh

Wells Fargo cuts Liquidia stock rating on patent ruling concerns

Wells Fargo downgraded Liquidia Technologies (LQDA) to Equal Weight, lowering its price target to $30.00 from $108.00 due to patent concerns and lower operating leverage. LQDA shares fell 59% in a week. The company reported Q2 2026 earnings, missing estimates but exceeding revenue expectations. A court ruling on patent infringement may impact L606 and YUTREPIA sales.

$AZNMedAI 8/10

Daiichi, AstraZeneca enter clinical trial cooperation with Summit

Daiichi Sankyo and AstraZeneca will collaborate with Summit Therapeutics on a phase 3 trial of Datroway and ivonescimab for triple-negative breast cancer. Datroway targets Trop-2, while ivonescimab targets PD-1 and VEGF. Each company will contribute its drug and share trial costs, retaining commercial rights. Daiichi Sankyo closed down 1.2% at JPY2,709.00, and AstraZeneca rose 0.2% to 12,058.00 pence on Friday.